The Selvax Project, based in Perth, is pursuing a novel immunological based approach to the treatment of large solid tumours. Led by Curtin University immunologist Dr Delia Nelson the team has made encouraging progress in the treatment of large solid tumours in animals by administration of selected immunological agents into the tumour micro environment. The technology has achieved cancer clearance rates in the range of 60%- 80% in repeated small animal studies for a range of solid tumours and has shown the capacity to protect against recurrence of the cancer.
Studies are about to commence in dogs in conjunction with a major veterinary oncology practice. In addition to its potentially broad application in humans the technology is believed to have commercial applications in veterinary oncology for companion animals, high value equine stock as well as in zoos.
